INTS vs XYL · $7.7M cap vs P/E 27, rev $8.56B
Intensity Therapeutics, Inc. Common stock (INTS) versus Xylem Inc (XYL) — a side-by-side from cached financials, not a winner call.
Intensity Therapeutics, Inc. Common stock (INTS) is a biotechnology company listed on US.
Xylem Inc (XYL) is a specialty industrial machinery company listed on NYSE.
INTS does not have a complete income-statement cache yet.
Latest reported XYL revenue for 2024-12-31 was $8.56B. Net income was $890.0M. Revenue was up 16.3% from 2023-12-31 to 2024-12-31. XYL currently screens at market cap $26.22B and trailing P/E 27.4.
INTS currently screens at market cap $7.7M. XYL currently screens at market cap $26.22B and trailing P/E 27.4.
Not investment advice. Open the INTS and XYL stock pages for the full models.
Not investment advice.